Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients

Inactivated Sendai virus particles (hemagglutinating virus of Japan envelope (HVJ-E)) have a novel antitumor effect: HVJ-E fused to prostate cancer cells via cell surface receptor causes apoptosis of prostate cancer cells in vitro and in vivo. HVJ-E also induces antitumor immunity by activating natu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, K, Nakai, Y, Kawashima, A, Ujike, T, Nagahara, A, Nakajima, T, Inoue, T, Lee, C M, Uemura, M, Miyagawa, Y, Kaneda, Y, Nonomura, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562845/
https://www.ncbi.nlm.nih.gov/pubmed/28497777
http://dx.doi.org/10.1038/cgt.2017.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562845/
https://www.ncbi.nlm.nih.gov/pubmed/28497777
http://dx.doi.org/10.1038/cgt.2017.15

Ejemplares similares